William Blair Starts Compass Therapeutics (CMPX) at Outperform
Tweet
Share
E-mailGet Alerts CMPX Hot Sheet
Rating Summary:
17 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
William Blair analyst Matt Phipps initiates coverage on Compass Therapeutics (NASDAQ: CMPX) with a Outperform rating.
The analyst comments "We are initiating coverage of Compass Therapeutics based largely on the potential success of lead program tovecimig, a DLL4xVEGF bispecific antibody , in patients with previously treated biliary tract cancer (BTC). Following positive top-line results on objective response rate (ORR), clinical outcome secondary endpoints are on track for disclosure at the end of first quarter 2026, when we believe positive progression-free survival (PFS) results will support regulatory filings with the FDA."
For an analyst ratings summary and ratings history on Compass Therapeutics click here. For more ratings news on Compass Therapeutics click here.
Shares of Compass Therapeutics closed at $5.17 yesterday.
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
William Blair, Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
